Share this article
Share this article
AUSTIN, Texas, March 9, 2021 /PRNewswire/ Clay A. Cauthen, MD, MA, is being recognized by Continental Who s Who as a Top Doctor in the field of Medicine for his professional excellence as a Transplant Cardiologist/Program Director for the Cardiology Fellowship Program with the Seton Heart Institute – Medical Park Tower/University of Texas Austin.
Leading an outstanding medical career for 15 years, Dr. Cauthen has garnered a well-deserving reputation for his professional excellence. He is a board-certified and fellowship-trained Transplant Cardiologist, currently serving patients at Seton Heart Institute – Medical Park Tower in Austin, Texas for the past seven years. He examines and treats patients with congenital heart defects, coronary artery disease, heart failure, valvular heart disease, and electrophysiology. Dedicated to keeping his patients well-informed, he also advises on the best course of action for his patients, spending time,
email article
An international committee proposed a universal definition for heart failure (HF) and two standard classifications that go beyond reduced and preserved left ventricular ejection fraction (LVEF). HF is a clinical syndrome with symptoms and or signs caused by a structural and or functional cardiac abnormality and corroborated by elevated natriuretic peptide levels and or objective evidence of pulmonary or systemic congestion, according to the consensus document from the Heart Failure Society of America (HFSA), European Society of Cardiology, and Japanese Heart Failure Society.
This is a slight difference from the definition of HF from the American College of Cardiology (ACC) and American Heart Association: a complex clinical syndrome that results from any structural or functional impairment of ventricular filling or ejection of blood.
BusinessWorld
February 17, 2021 | 11:44 am
Dapagliflozin has been approved by the Food and Drug Administration (FDA) to treat heart failure in adults with reduced ejection fraction (HFrEF) in the Philippines.
The results of the trial showed that dapagliflozin adds to other guideline-recommended therapies in reducing the risk of mortality and heart failure hospitalization. It also improves symptoms in patients with HFrEF.
A total of 4,744 patients 22 to 94 years of age with a mean age of 66.3 years were randomized for the trial. The benefit of dapagliflozin was found consistent in both older and younger patients.
“Patients with a history of recurrent urinary tract infection or genital infection should be careful [when taking dapagliflozin],” said Dr. David K. Sim, president of Singapore’s Heart Failure Society, in response to a question about the medication’s contraindications during a February 16 discussion organized by AstraZeneca Philippines. “We
email article
After the all-male (and largely white) faculty lineup at the Heart Failure 2021 virtual meeting from Los Angeles drew ire on Twitter, organizers made swift changes.
Both program directors and all 23 speakers originally scheduled to lecture at the small subspecialty symposium March 12-13 are men. Gentleman, it s 2021 and there are soooooo many women in heart failure for this entire conference to be all men. Do better, Nasrien E. Ibrahim, MD, of Massachusetts General Hospital in Boston, tweeted on Wednesday with pictures of the then-current faculty list.
Ironically, Wednesday was also National Women Physicians Day.
Ibrahim called out the organizers for lack of effort, writing you didn t search hard enough. Others weren t so generous.
(Photo by Paul ELLIS / AFP / MANILA BULLETIN)
With the FDA’s approval, Dapagliflozin is the first and only drug under the sodium glucose transport protein 2 inhibitor (SGLT2i) class approved to treat heart failure in adult patients with reduced ejection fraction (pumapalyang puso), AstraZeneca Philippines said in statement.
The multinational pharmaceutical company noted that the Dapagliflozin, a medicine for diabetes, is the only SGLT2i proven to significantly prevent cardiovascular death and death due to other causes among patients with heart failure.
AstraZeneca Philippines Country President Lotis Ramin expressed AstraZeneca’s commitment to uplift the standard of care of Filipino patients by providing them with innovative and accessible treatment.